Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome

NCT07702981 · clinicaltrials.gov ↗

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Membranous Nephropathy
Minimal Change Disease (MCD)
Focal Segmental Glomerulosclerosis (FSGS)

Interventions

DRUG: Rituximab (MABTHERA® or RITUXAN®).
DRUG: Corticosteroids (CS)
DRUG: Corticosteroids (CS)

Sponsor

University Hospital, Ioannina